Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Lalloo DG, Jacobs M, Griffiths G. Khoo SH, et al. Among authors: pertinez h. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318. J Antimicrob Chemother. 2021. PMID: 34450619 Free PMC article. Clinical Trial.
Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection.
Sibley L, White AD, Sarfas C, Gullick J, Gleeson F, Lanni F, Clark S, Rayner E, Ferrer-Bazaga S, Ortega-Muro F, Alameda L, Rullas J, Sousa V, Martinez M, Angulo-Barturen I, Garcia A, Vaquero JJ, Pertinez HE, Davies G, Dennis M, Williams A, Sharpe S. Sibley L, et al. Pharmaceutics. 2022 Nov 30;14(12):2666. doi: 10.3390/pharmaceutics14122666. Pharmaceutics. 2022. PMID: 36559163 Free PMC article.
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Arshad U, et al. Among authors: pertinez h. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. Clin Pharmacol Ther. 2020. PMID: 32438446 Free PMC article. Review.
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
McCallum AD, Pertinez HE, Else LJ, Dilly-Penchala S, Chirambo AP, Sheha I, Chasweka M, Chitani A, Malamba RD, Meghji JZ, Gordon SB, Davies GR, Khoo SH, Sloan DJ, Mwandumba HC. McCallum AD, et al. Among authors: pertinez he. Clin Infect Dis. 2021 Nov 2;73(9):e3365-e3373. doi: 10.1093/cid/ciaa1265. Clin Infect Dis. 2021. PMID: 32856694 Free PMC article.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini GA, Owen A. Rajoli RKR, et al. Among authors: pertinez h. Br J Clin Pharmacol. 2021 Apr;87(4):2078-2088. doi: 10.1111/bcp.14619. Epub 2020 Dec 1. Br J Clin Pharmacol. 2021. PMID: 33085781 Free PMC article.
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.
Walker LE, FitzGerald R, Saunders G, Lyon R, Fisher M, Martin K, Eberhart I, Woods C, Ewings S, Hale C, Rajoli RKR, Else L, Dilly-Penchala S, Amara A, Lalloo DG, Jacobs M, Pertinez H, Hatchard P, Waugh R, Lawrence M, Johnson L, Fines K, Reynolds H, Rowland T, Crook R, Okenyi E, Byrne K, Mozgunov P, Jaki T, Khoo S, Owen A, Griffiths G, Fletcher TE; AGILE platform. Walker LE, et al. Among authors: pertinez h. Clin Pharmacol Ther. 2022 Mar;111(3):585-594. doi: 10.1002/cpt.2463. Epub 2021 Nov 13. Clin Pharmacol Ther. 2022. PMID: 34699618 Free PMC article. Clinical Trial.
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis.
McCallum AD, Pertinez HE, Chirambo AP, Sheha I, Chasweka M, Malamba R, Shani D, Chitani A, Mallewa JE, Meghji JZ, Ghany JF, Corbett EL, Gordon SB, Davies GR, Khoo SH, Sloan DJ, Mwandumba HC. McCallum AD, et al. Among authors: pertinez he. Clin Infect Dis. 2022 Oct 29;75(9):1520-1528. doi: 10.1093/cid/ciac228. Clin Infect Dis. 2022. PMID: 35325074 Free PMC article.
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.
Chang YS, Li SY, Pertinez H, Betoudji F, Lee J, Rannard SP, Owen A, Nuermberger EL, Ammerman NC. Chang YS, et al. Among authors: pertinez h. Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0048123. doi: 10.1128/aac.00481-23. Epub 2023 Jun 14. Antimicrob Agents Chemother. 2023. PMID: 37338374 Free PMC article.
50 results